Format

Send to

Choose Destination
J Neurovirol. 2016 Aug;22(4):431-41. doi: 10.1007/s13365-015-0410-7. Epub 2015 Dec 4.

Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV.

Author information

1
Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. ajlevine@mednet.ucla.edu.
2
Department of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA.
3
Departments of Psychiatry and Pathology, University of California San Diego School of Medicine, La Jolla, CA, USA.
4
Departments of Neurosciences and Pathology, University of California San Diego School of Medicine, La Jolla, CA, USA.
5
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
6
Departments of Human Genetics and Biomathematics, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
7
Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.

Abstract

The neuropathogenesis of HIV-associated neurocognitive disorders (HAND) remains puzzling. We interrogated several levels of data (host genetic, histopathology, brain viral load, and neurocognitive) to identify histopathological changes most relevant to HAND. The design of the study is a clinicopathological study employing genetic association analyses. Data and brain tissue from 80 HIV-infected adults were used. Markers in monocyte chemoattractant protein-1 (MCP-1), interleukin 1-alpha (IL1-α), macrophage inflammatory protein 1-alpha (MIP1-α), DRD3, DRD2, and apolipoprotein E (ApoE) were genotyped. Microtubule associated protein 2 (MAP2), synaptophysin (SYP), human leukocyte antigen-DR (HLA-DR), glial fibrillary acidic protein (GFAP), amyloid beta (A-Beta), and ionized calcium-binding adaptor molecule-1 (Iba-1) immunoreactivity were quantified in the frontal cortex, putamen, and hippocampus. A composite score for each marker (mean of the three brain regions) was used. Neurocognitive functioning and other clinical variables were determined within 1 year of death. Brain HIV RNA viral load was available for a subset of cases. MAP2 and SYP proved most relevant to neurocognitive functioning. Immunoreactivity of these markers, as well as A-Beta and Iba-1, was correlated with brain HIV RNA viral load. Several genetic markers in combination with other factors predicted histopathology: HIV blood viral load, MIP1-α genotype, and DRD3 genotype predicted Iba-1 immunoreactivity; the duration of infection and IL1-α genotype predicted GFAP immunoreactivity; ApoE genotype and age at death predicted A-Beta immunoreactivity. These data indicate that HIV replication in the brain is the primary driving force leading to neuroinflammation and dysfunctional protein clearance, as reflected by A-Beta and Iba-1. Downstream to these changes are synaptodendritic degeneration, which is the immediate histopathological substrate of the neurocognitive impairment characteristic of HAND. These intermediate histopathological phenotypes are influenced by host genetic polymorphisms in genes encoding cytokines/chemokines, neuronal protein clearance pathways, and dopaminergic factors.

KEYWORDS:

HIV; HIV-associated neurocognitive disorders; Histopathology; Host genetic; NeuroAIDS; Synaptodendritic

PMID:
26637429
PMCID:
PMC4893344
DOI:
10.1007/s13365-015-0410-7
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Publication type

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center